title: Hyperprolactinemia, prolactin-related side effects and quality of life in Chinese psychiatric patients.
abstract: To examine the frequency of hyperprolactinemia and the socio-demographic, clinical, and quality of life (QOL) correlates. The frequency of prolactin-related side effects and associated subjective experiences were also examined.
  
  
  
  A cohort of 1364 psychiatric inpatients were consecutively recruited and evaluated. Basic socio-demographic and clinical data were collected. Psychopathology, prolactin-related side effects were measured using standardized instruments. QOL was assessed using the Medical Outcomes Study Short Form 12.
  
  
  
  The frequency of hyperprolactinemia was 61.3% in the whole sample; 61.6% in female and 60.8% in male patients. There was no significant association between hyperprolactinemia and any QOL domain. In the whole sample, 15.1% of patients reported moderately severe breast symptoms and lactation, and 53.9% reported moderate or severe discomfort. Nearly a third of female patients (30.4%) reported at least moderate menstrual changes and 50.2% moderate or severe discomfort, while 24.2% of male patients reported at least moderate erectile dysfunction and 52.6% moderate or severe discomfort. Multiple logistic regression analysis revealed that patients with hyperprolactinemia were less likely to be married, diagnosed with mood disorders, or treated with clozapine, aripiprazole, or antidepressants but more likely to receive risperidone.
  
  
  
  Effective measures to lower the frequency of hyperprolactinemia and the related side effects should be considered in Chinese psychiatric facilities.
authors.affiliation: National Clinical Research Center for Mental Disorders & Beijing Anding Hospital, Capital Medical University, China.
authors.forename: Feng-Rong
authors.initials: FR
authors.lastname: An
authors.affiliation: National Clinical Research Center for Mental Disorders & Beijing Anding Hospital, Capital Medical University, China.
authors.forename: Rui
authors.initials: R
authors.lastname: Yang
authors.affiliation: National Clinical Research Center for Mental Disorders & Beijing Anding Hospital, Capital Medical University, China.
authors.forename: Zhi-Min
authors.initials: ZM
authors.lastname: Wang
authors.affiliation: The University of Notre Dame Australia/Marian Centre, Perth, Australia; School of Psychiatry & Clinical Neurosciences, University of Western Australia, Perth, Australia.
authors.forename: Gabor S
authors.initials: GS
authors.lastname: Ungvari
authors.affiliation: Department of Psychiatry, University of Melbourne, Melbourne, Victoria, Australia.
authors.forename: Chee H
authors.initials: CH
authors.lastname: Ng
authors.affiliation: Department of Psychiatry, Chinese University of Hong Kong, Hong Kong, SAR, China.
authors.forename: Helen F K
authors.initials: HF
authors.lastname: Chiu
authors.affiliation: National Clinical Research Center for Mental Disorders & Beijing Anding Hospital, Capital Medical University, China.
authors.forename: Ping-Ping
authors.initials: PP
authors.lastname: Wu
authors.affiliation: National Clinical Research Center for Mental Disorders & Beijing Anding Hospital, Capital Medical University, China.
authors.forename: Xin
authors.initials: X
authors.lastname: Jin
authors.affiliation: Unit of Psychiatry, Faculty of Health Sciences, University of Macau, Macao, SAR, China.
authors.forename: Lu
authors.initials: L
authors.lastname: Li
authors.affiliation: Unit of Psychiatry, Faculty of Health Sciences, University of Macau, Macao, SAR, China; Kiang Wu Nursing College of Macau, Macao, SRA, China.
authors.forename: Grace K I
authors.initials: GK
authors.lastname: Lok
authors.affiliation: Unit of Psychiatry, Faculty of Health Sciences, University of Macau, Macao, SAR, China. Electronic address: xyutly@gmail.com.
authors.forename: Yu-Tao
authors.initials: YT
authors.lastname: Xiang
mesh_terms: D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D000068180:Aripiprazole / Q000627:therapeutic use; D016022:Case-Control Studies; D002681:China / Q000453:epidemiology; D003024:Clozapine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000453:epidemiology*; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy / Q000453:epidemiology*; D011788:Quality of Life; D018967:Risperidone / Q000627:therapeutic use; D012735:Sexual Dysfunction, Physiological / Q000139:chemically induced / Q000453:epidemiology*; D055815:Young Adult
chemical_list: D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D000068180:Aripiprazole; D003024:Clozapine; D018967:Risperidone